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Abstract
Introduction: There are little data on the clinical activity of 
temsirolimus (TM) and everolimus (EV) when used as second-line 
therapy after sunitinib (SU) in patients with metastatic renal cell 
carcinoma (mRCC).
Methods: Patients with mRCC treated with EV or TM after SU were 
included in this retrospective analysis. Progression-free survival 
(PFS), time to sequence failure (TTSF) from the start of SU to disease 
progression with EV/TM and overall survival (OS) were estimated 
using Kaplan-Meier method and compared across groups using 
the log-rank test. Cox proportional hazards models were applied 
to investigate predictors of TTSF and OS.
Results: In total, 89 patients (median age 60.0 years) were included. 
At baseline 43% were classified as MSKCC good-risk, 43% as inter-
mediate-risk and 14% as poor-risk. Median OS was 36.3 months 
and median TTSF was 17.2 months. Sixty-five patients received 
SU-EV and 24 patients SU-TM. Median PFS after the second-line 
treatment was 4.3 months in the EV group and 3.5 months in the 
TM group (p = 0.63). Median TTSF was 17.0 and 18.9 months 
(p = 0.32) and the OS was 35.8 and 38.3 months (p = 0.73) with 
SU-EV and SU-TM, respectively. The prognostic role of initial 
MSKCC was confirmed by multivariable analysis (hazard ratio 
1.76, 95% confidence interval 1.08-2.85. p = 0.023).
Conclusions: This study did not show significant differences in 
terms of disease control and OS between EV and TM in the second-
line setting. EV remains the preferred mTOR inhibitor for the treat-
ment of mRCC patients resistant to prior tyrosine kinase inhibitor 
treatment.
Introduction 
Metastatic renal cell carcinoma (mRCC) is the most fatal of 
all urological cancers, with 5-year survival rates of about 
10%.1,2 In the past decade the following vascular endothe-
lial growth factor (VEGF)/VEGF receptors (VEGFR) have been 
developed: sorafenib, sunitinib, pazopanib, axitinib, tivoza-
nib and bevacizumab (in combination with interferon), and 
2 mTOR inhibitors have been developed for the treatment 
of mRCC. Temsirolimus (TM) and everolimus (EV) are cur-
rently the only mTOR inhibitors approved by the Food and 
Drug Administration (FDA) and the European Medical Agency 
(EMA) for the treatment of mRCC. In contrast to anti-angio-
genic agents, mTOR inhibitors act mainly in tumour cells 
where they inhibit genes related to angiogenesis binding to 
the immunophilin FK binding protein-12 (FKBP-12); these 
inhibitors then generate an immunosuppressive complex that 
inhibits the activation of the mammalian target of rapamycin 
(mTOR), a key kinase regulatory of cell growth, proliferation, 
motility, survival as well as in protein synthesis, and transcrip-
tion.3,4 TM is used in the treatment of poor prognosis patients 
following results of a phase III trial in 626 previously untreat-
ed patients with poor prognosis.5 Compared with interferon 
(IFN) and TM plus IFN, TM monotherapy improved overall 
survival (OS) in patients with mRCC and a poor prognosis.5 
In another large phase III trial in 410 patients previously pre-
treated with one or more antiangiogenic agents, randomized 
to receive EV or placebo, there was a significant increase in 
progression-free survival (PFS) in patients treated with EV. 
However, there was no significant improvement in terms of 
OS, probably because most patients treated in the placebo 
arm crossed over to the EV arm.6 In 2012, Chen and col-
leagues published a real-world data analysis of 257 patients 
with mRCC who were receiving second-line EV, sorafenib 
(SO), or TM after first-line SU. They concluded that the risk 
of second-line treatment failure after first-line SU was signifi-
cantly higher with TM and SO compared with EV.7 
To further investigate the clinical efficacy of these agents, 
we retrospectively analyzed clinical outcomes in a selected 
group of patients who received SU as first-line, and EV and 
TM as second-line therapy.
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In this retrospective analysis, we reviewed patients with 
mRCC treated with EV or TM after first-line SU in the main 
centres involved in kidney cancer treatment in Italy. We 
only included patients with clear cell histology and measur-
able disease. For each patient, information on the date of 
nephrectomy, initial prognostic class based on Memorial 
Sloan Kettering Cancer Centre (MSKCC) criteria, the type and 
length of the first-, second- and third-line therapy were col-
lected.8 Two sequences of therapy were considered: (1) SU 
followed by EV (SU-EV) and (2) SU followed by TM (SU-TM).
All patients received SU at a starting dose of 50 mg/day 
for 4 weeks every 6 weeks. On disease progression, patients 
were treated with EV (starting dose 10 mg/day orally or TM 
(starting dose 25 mg intravenously) every week. Patients 
were treated until disease progression (DP) or an unaccept-
able level of toxicity. Response assessment by computed 
tomography (CT) or magnetic resonance imaging (MRI) 
scans was carried out according to local procedures every 
8 to 12 weeks. DP was defined as a ≥20% increase of the 
longer diameter, according to the for RECIST (Response 
Evaluation Criteria In Solid Tumours) 1.0 criteria.9 Values 
were expressed as median and interquartile range (IQR). PFS 
was defined as the time from beginning of treatment to DP 
or to death from any cause, whichever occurred first. Time 
to sequence failure (TTSF) was defined as the time from the 
start of SU to the first documentation of DP with EV or TM 
or to death from any causes, whichever occurred first. OS 
was defined as the time from start of SU to death or last 
contact. PFS, TTSF and OS were estimated using Kaplan-
Meier method with Rothman’s 95% confidence intervals 
(CI) and compared across groups using the log-rank test. 
The Chi-Square test was used to assess differences between 
groups. Cox proportional hazards models were applied to 
study patient characteristics as predictors of TTSF and OS 
in univariate- and multivariable-adjusted analysis using a 
stepwise selection approach with type I error of 0.05 for 
model entry and 0.10 for elimination. Additional elimina-
tion was applied to identify significant variables at the level 
of p < 0.05, using PASW (Predictive Analytics SoftWare, v. 
18, IBM SPSS, Cary, NC).
Results 
A total of 89 patients with mRCC were treated with first-line 
SU followed by EV or TM at 19 Italian centres. An average of 3 
patients were treated at each centre and EV was the most used 
second-line treatment among the available ones in 18 out of 
24 centres. The median age was 60.0 years (IQR: 55.4-68.2); 
76% of patients were male; 93% had had a radical nephrec-
tomy and 40% were metastatic at diagnosis. The MSKCC 
prognostic group at the first-line treatment was good in 43%, 
intermediate in 43% and poor in 14% of patients. Median 
OS was 36.3 months (95% CI, 31.5-41.0); when stratified by 
MSKCC classification, this was 70.1 months (95% CI, 33.6-
106.5) in the good prognosis group, 36.3 months (95% CI, 
30.4-42.1) in the intermediate group and 24.6 months (95% 
CI, 10.0-39.1) in the poor prognostic group (p < 0.0001). 
Effects of sequencing with SU-EV or SU-TM 
Sixty-five patients received SU-EV and 24 SU-TM and some 
patients went on to receive third-line therapy with other 
targeted agents. Median PFS at first line was 11.0 months 
(95% CI, 8.1-13.9), with no significant differences between 
the 2 sequencing groups (Table 1). 
Median PFS at second line was 4.3 months (95% CI, 
3.7-4.8) in patients treated with EV and 3.5 months (95% 
CI, 3.8-4.5) in those treated with TM; differences were not 
significant between the 2 groups (p = 0.63).
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Male sex 76% 69% 91% 0.04




  Good 43% 48% 41%
  Intermediate 43% 46% 45%
  Poor 14% 6% 14%
PFS first line (months) 11.0 11.2 8.5 0.88*
SU-EV: sunitinib-everolimus; SU-TM: sunitinib-temsirolimus; IQR: interquartile range; MSKCC: Memorial Sloan Kettering Cancer Center; PFS: progression-free survival; *log-rank test.  
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When the 2 sequences were considered, the TTSF was 
17.0 (95% CI, 13.8-20.2) and 18.9 (95% CI, 15.1-22.7) 
months and the OS was 35.8 (95% CI, 32.2-39.4) and 38.3 
(95% CI, 18.9-57.7) months for the sequence SU-EV and 
SU-TM, respectively. No significant differences were found 
for TTSF (p = 0.32) and OS (p = 0.73) (Fig. 1). 
Partial responses were reported in 13% and 14% of 
patients treated with  EV and TM respectively; stable disease 
and DP in 47% and 40% of patients who received EV and 
in 45% and 41% of patients who received TM. There were 
no significant differences between the 2 groups (p = 0.99).
Overall 88% received SO as third-line therapy (86% in 
the SU-EV and 91% in the SU-TM group) and the remain-
ing patients had a re-challenge with SU or a combination 
of therapies or were enrolled in clinical trials.
Univariate and multivariable analysis for TTSF and OS 
The initial MSKCC prognostic group and the primary resis-
tance to SU were predictive factors on univariate analysis, 
but their role was not confirmed by multivariable analysis 
(Table 2).
Moreover, the initial MSKCC prognostic group was an 
independent prognostic factor in patients treated with EV 
or TM after SU failure (hazard ratio [HR]: 1.76, 95% CI, 
1.08-2.85, p = 0.023) (Table 2).
Discussion
EV is a standard therapy in the management of mRCC that 
has progressed following a tyrosine kinase inhibitor (TKI), 
such as SU or SO. The RECORD-1 trial reported a significant 
increase in PFS (from 1.9 to 4.9 months) with EV compared 
with placebo, especially in patients treated with first-line 
SO (5.9 vs. 2.8 months) compared to SU (3.9 versus 1.8 
months).10 In fact, SU was a negative predictive factor for 
EV activity in the multivariate analysis. Despite this, our 
data confirm the activity of EV and show a median PFS of 
4.3 months and a disease control rate of 60% in a homog-
enous group of patients treated with first-line SU. The activ-
ity of TM in previously treated patients has been studied in 
2 small retrospective studies, with a median PFS ranging 
from 2.5 to 4.0 months and a clinical response in 90% of 
patients.11,12 In a larger retrospective study MacKenzie and 
colleagues reported the activity of TM in 87 mRCC patients 
treated in 3 centres in the United States and Canada.13 The 
study enrolled patients who had progressed after SU (85%) 
and in intermediate prognostic group. Patients treated with 
TM showed either a partial response (5%) or stable dis-
ease (65%) with median time to progression (TTP) and OS 
3.9 and 11.2 months, respectively. Milella and colleagues 
reported the results of a large prospective phase II trial with 
TM in patients pre-treated with antiangiogenic agents (43% 
with SU). Results showed a median PFS of 4.0 months, with 
a median PFS and OS in those who had previously been 
treated with SU of 4.6 and 13.7 months, respectively.14  
Similarly to our study, Chen and colleagues evaluated 
treatment outcomes associated with EV, TM after first-line 
SU. Patients were followed from the start of second-line 
treatment until treatment failure (defined as advancement 
to a third-line therapy or to mortality). The estimated 1-year 
cumulative probabilities of treatment failure were 49.9% 
outcomes in patients with metastatic rcc
Fig. 1. Time to sequence failure (TTSF) and overall survival (OS) in patients received sunitinib followed by everolimus (blue) or sunitinib followed by temsirolimus (red).
for EV, 68.4% for SO, and 71.4% for TM. In a multivari-
ate Cox proportional hazards model, a higher adjusted risk 
of treatment failure versus EV was observed for both TM 
and SO. The authors concluded that this real-world data 
analysis suggests that the risk of second-line treatment fail-
ure after first-line SU was significantly higher with TM and 
SO compared with EV; this is in contrast with the results of 
our study where we found the lack of difference between 
EV and TM after first-line SU. However, OS in our study 
was not comparable to our previous experience or with the 
results of published trials, mainly because our cohort was 
highly selected in that all patients had clear cell histology, 
had first-line therapy with SU and were treated with mTORs 
only as second line. Moreover, patients went on to receive 
third-line therapy with other targeted agents. As a result of 
this selection, median OS was about 3 years and up to 6 
years in the good prognostic group. 
Our study is not without limitations. Its applicability to all 
patients with mRCC is limited by its retrospective nature, the 
lack of central radiologic review for the CT scans performed 
during the treatment, and the difference in the number of 
patients who received EV and TM. These may affect the 
overall evaluation of the response and assessment of the PFS. 
Our results need to be confirmed in prospective randomized 
trials, but it is important to recall that data on the efficacy of 
TM have been reported at the European Society for Medical 
Oncology (ESMO) 2012 conference and the results of the 
INTORSECT phase III trial (NCT00474786). There were no 
differences in terms of PFS between TM and SO (4.3 vs. 
3.9 months; HR: 0.87, 95% CI, 0.71-1.07; p = 0.193), but 
there was a significant shorter survival in patients treated 
with TM (12.3 vs. 16.6 months; HR: 1.31, 95% CI, 1.05-
1.63; p = 0.014).15 
Overall, these results are not conclusive on the role of 
mTOR inhibitors in the treatment of mRCC. A direct com-
parison between the activities of TM, EV and SO based on 
our findings is not possible taking in account our reported 
limitations. Much debate surrounds the “best” second-line 
strategy in mRCC, but results to date seem to suggest that 
the use of TM should be avoided in patients progressed after 
SU. Finally, this study did not show significant differences 
in terms of disease control and OS between EV and TM 
in the second-line setting, where EV remains the preferred 
mTOR inhibitor for treatment of mRCC patients resistant to 
prior TKI treatment.
Conclusion 
In patients with mRCC who progress on antiangiogenic 
treatment, EV remains the standard of care if switching to a 
mTOR inhibitor is the strategy.
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